Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<ul><li>The agrochemical company <keyword id="13053010" type="General" weightage="100" keywordseo="dharmaj-crop-guard" source="Orion">Dharmaj Crop Guard</keyword> is likely to announce its share allotment status on December 5. </li><li>Overall, the IPO saw decent demand from investors amidst volatile market conditions, being subscribed 35.49 times. </li><li>The shares will be listed on December 8 on the exchanges. </li></ul>The agrochemical company Dharmaj Crop Guard is likely to announce the allotment status of its initial public offering (IPO) on Monday, December 5. Overall, the IPO received decent demand from investors amidst volatile market conditions, being subscribed 35.49 times. The qualified institutional buyer portion was subscribed 48.21 times. The portion reserved for non-institutional investors witnessed a subscription of 52.29 times. The retail portion, on the other hand, was subscribed 21.53 times. The grey market premium (GMP) for the company’s shares stood at ₹55 per share. The Ahmedabad-based agrochemical company distributes and markets insecticides, fungicides, herbicides, plant growth regulators, micro fertilisers and antibiotics to the B2B and B2C segments. Here is how to check <keyword id="15699155" type="General" weightage="20" keywordseo="Dharmaj-Crop-Guard-IPO-allotment-status" source="Orion">Dharmaj Crop Guard IPO allotment status</keyword> on the stock exchange websites: <ul><li>Go to the <a href="https://www.bseindia.com/investors/appli_check.aspx">BSE website</a> or NSE website<a href="https://www1.nseindia.com/products/dynaContent/equities/ipos/ipo_login.jsp"> here</a>. </li><li>On <keyword id="35140" type="General" weightage="50" keywordseo="bse" source="Orion">BSE</keyword>, Select 'Equity' and then from the dropdown, select ‘Dharmaj Crop Guard’. </li><li>Now, enter your application number and PAN. </li><li>Click on 'Search'. </li><li>Please note the details will only be available once the shares are allotted. </li></ul>You can also visit the registrar website (Link Intime India) to check your application status. <ul><li>Visit the registrar's website <a href="https://linkintime.co.in/MIPO/Ipoallotment.html">here</a>. </li><li>Click on 'Select company' and click on ‘Dharmaj Crop Guard’. </li><li>Once the company is selected, you will have to enter either your PAN details, the application number, or the client ID. </li><li>Enter the captcha code and click ’submit’. </li></ul>Once you hit 'submit', the status of your application will appear on the screen. Please ensure the details that you provide are correct. It will show the number of shares you subscribed to and the number of shares allotted to you. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/finance/news/bank-of-baroda-expects-25-35-basis-points-rate-hike-from-dec-5-7-rbi-policy-meet/articleshow/95992359.cms">Bank of Baroda expects 25-35 basis points rate hike from Dec 5-7 RBI policy meet</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/startups/news/this-mumbai-startup-is-making-tearable-laundry-sheets-bamboo-based-facial-tissues-and-more-to-replace-plastic/articleshow/95946533.cms">This Mumbai startup is making tearable laundry sheets, bamboo-based facial tissues and more to replace plastic</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/science/news/govt-approves-pli-scheme-for-making-drones-with-outlay-of-rs-120-cr-comes-out-with-norms/articleshow/95981288.cms">Govt approves PLI scheme for making drones with outlay of Rs 120 cr, comes out with norms</a>

Dharmaj Crop Guard IPO : Here’s how you can check the allotment status

<ul><li>The company said in a statement that it "had to take the tough decision to let go 150 of our team members".</li><li>The platform offered a severance package of two months to the laid-off employees, with two weeks per year served at the startup.</li><li>According to the company, it caters to more than 30 million users in over 300 cities with over 2,000 coaches.</li></ul>Leading AI health and fitness platform <keyword id="2698623" type="General" weightage="100" keywordseo="healthifyme" source="Orion">HealthifyMe</keyword> has sacked at least 150 employees as the company's growth did not "keep pace with expectations and hiring". The company has a physical presence in Bengaluru, Delhi, Mumbai, Chennai and Singapore. The company said in a statement that it "had to take the tough decision to let go 150 of our team members". "Like much of tech, growth hasn't kept pace with expectations and hiring," the company added. The platform offered a severance package of two months to the laid-off employees, with two weeks per year served at the startup. "As a part of our severance and support to those impacted, we will offer 2 months' salary severance with 2 weeks per year served at HealthifyMe, vested stocks till March 2023, and medical insurance continuance till June 2023, along with counseling and outplacement support," said the company. According to the company, it caters to more than 30 million users in over 300 cities with over 2,000 coaches. The <keyword id="2534058" type="General" weightage="20" keywordseo="healthtech" source="Orion">healthtech</keyword> platform in July this year raised $75 million (nearly Rs 560 crore) in a Series C round led by <keyword id="15700419" type="General" weightage="50" keywordseo="leapfrog-and-khosla-ventures" source="Orion">LeapFrog and Khosla Ventures</keyword>. The company aimed to use the funds to expand in <keyword id="3658" type="General" weightage="50" keywordseo="india" source="Orion">India</keyword> and <keyword id="53564" type="General" weightage="50" keywordseo="southeast-asia" source="Orion">Southeast Asia</keyword>, make inroads into <keyword id="6378080" type="General" weightage="50" keywordseo="north-america" source="Orion">North America</keyword> as well as to acquire relevant companies in the digital health and fitness space. "We are already the market leaders in India and Southeast Asia and by combining AI and human empathy, we can deliver results in weight and lifestyle disease management at a fraction of the cost possible today," Tushar Vashisht, Co-founder and CEO, HealthifyMe, had said in a statement. While HealthifyMe's base has been India, it has been expanding internationally and now nearly 25 per cent of its revenues come from outside the country like Malaysia and Singapore, it had said in July. The company had also said to hire over 1,000 trainers and coaches this year. "We are also undergoing an evolution with our new vision around metabolic health (HealthifyMe 2.0) which requires different resources. In view of this and changing market dynamics, it made sense for us to steer toward profitability, despite a comfortable runway," the company spokesperson said in the latest statement. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/entertainment/news/ayushmann-khurranas-doctor-g-set-for-ott-debut-on-netflix/articleshow/95995391.cms">Ayushmann Khurrana's 'Doctor G' set for OTT debut on Netflix</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/expect-nifty-to-end-the-december-series-on-a-positive-note-reach-a-target-of-18900-19000-says-r-venkataraman-of-iifl-securities/articleshow/95992944.cms">Expect Nifty to end the December series on a positive note, reach a target of 18,900-19,000, says R Venkataraman of IIFL Securities</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/finance/news/dharmaj-crop-guard-ipo-how-you-can-check-the-allotment-status/articleshow/95992589.cms">Dharmaj Crop Guard IPO : Here’s how you can check the allotment status</a>

HealthifyMe sacks about 150 employees, says growth didn't keep pace with hiring

<ul><li>GLP1 receptor agonists and SGLT2 inhibitors — are the new types of drugs which have been found to be effective in helping diabetics lose weight. </li><li>These drugs remove glucose from the body via urinary excretion, thereby removing calories from the body. </li><li><keyword id="3658" type="General" weightage="80" keywordseo="india" source="Orion">India</keyword> has only one approved <keyword id="6358794" type="General" weightage="20" keywordseo="weight-loss" source="Orion">weight loss</keyword> drug and that too is very mild, doctors say and helps lose only 4% of body weight. </li></ul>People who take diabetic drugs often witness changes in their body weight during the course of their treatment. However, new anti-diabetic drugs coming in the market are found to be very effective in weight loss, in addition to controlling blood glucose levels. Does that mean these drugs can be used for the purpose they are not originally intended – only for weight loss? The world’s richest man and the new owner of Twitter, <keyword id="6355315" type="General" weightage="80" keywordseo="elon-musk" source="Orion">Elon Musk</keyword> seems to think so. <div type="twitter" handle="elonmusk" handlename="Elon Musk" image="http://pbs.twimg.com/profile_images/1590968738358079488/IY9Gx6Ok_normal.jpg" favoritecount="4414" retweetcount="287" status="@teslaownersSV @chicago_glenn @stillgray @dcherring @nichegamer Fasting + Ozempic/Wegovy + no tasty food near me" createdat="1668580581000" id="1592768518050574336"></div> In a tweet, he credited <keyword id="14638097" type="General" weightage="80" keywordseo="wegovy" source="Orion">Wegovy</keyword> as his secret of losing over 13 kilos. Wegovy is an injectable type-2 <keyword id="6359018" type="General" weightage="20" keywordseo="diabetes" source="Orion">diabetes</keyword> drug by Novo Nordisk, which is also indicated for weight loss. How do these drugs cause weight loss? Apart from the injectable, GLP1 receptor agonists and SGLT2 inhibitors are other types of diabetic drugs available in the market that have been found to be effective for weight loss. “These drugs act through various mechanisms, for instance, they work by increasing the removal of glucose from the body via urinary excretion, thereby leading to the loss of calories from the body,” Dr Brij Mohan <keyword id="76127" type="General" weightage="80" keywordseo="makkar" source="Orion">Makkar</keyword>, senior diabetologist, president RSSDI told Business Insider India. According to <keyword id="15635207" type="General" weightage="80" keywordseo="dr-makkar" source="Orion">Dr Makkar</keyword>, Inj Semaglutide 2.4 mg (Wegovvy), which is FDA-approved and is a GLP1 receptor agonist, is said to be the most popular anti-diabetic weight loss drug. Inj Semaglutide drug acts on the brain to reduce appetite, slow gastric emptying, and reduce blood pressure to some extent, all of which have favourable effects on the metabolism. This drug suppresses appetite through its action on the brain, which gives a feeling of fullness. “The drug has been studied in many clinical trials and found safe. The injection needs to be taken once a week and continued for the long term,” Dr Makkar said. He also believes that they do not cause major side effects. “The side effects, if any, are usually mild and subside shortly after treatment initiation,” he added. Are they affordable? In addition to weight loss, anti-diabetic drugs help control other metabolic diseases too. GLP1 receptor agonists and SGLT2 inhibitors also help protect against cardiovascular events. “These classes of drugs showed cardiovascular benefits in studies,” Dr Reddy added. SGLT2 drugs also help in preventing heart failures and are now being used as the first treatment by cardiologists, even among non-diabetics, according to Dr Mohan. Other drugs like <keyword id="123712" type="General" weightage="80" keywordseo="metformin" source="Orion">Metformin</keyword> (Biguanide family),Glucosidase inhibitors are found to be effective in losing weight. “Metformin remains the primary treatment in type 2 Diabetes. Its mechanism is at central hypothalamic and peripheral gastrointestinal effects glucosidase inhibitor by delaying carbohydrate absorption from gastrointestinal tract,” Dr Somashekara Reddy, consultant - diabetology &amp; endocrinology, Fortis Hospitals, Bangalore told Business Insider India. Another diabetic drug called Liraglutide is recommended by doctors for purely weight loss in many countries like the USA, even among non-diabetics, Dr Mohan added. However, none of the SGLT2 inhibitors have received approval for weight loss so far, in India. Weight loss drugs themselves are few in India. “Currently, only one approved weight loss drug is available in India, and it acts by blocking the absorption of fat. But the drawback is that it is a very mild drug and helps in losing only about 4% of the body weight. It acts differently than diabetes weight loss drugs,” Dr Makkar said. Dr Mohan also highlighted that these two classes of drugs – GLP1 and SGLT2 agent drugs — are highly expensive and beyond the reach of a common man. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/indian-markets-open-lower-amid-unrest-in-china-over-zero-covid-paytm-adani-transmission-hero-motocorp-in-focus/articleshow/95815834.cms">Indian markets open lower amid unrest in China over zero-Covid: Paytm, Adani Transmission, Hero MotoCorp in focus</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/international/news/canada-to-strengthen-visa-processing-capacity-in-delhi-and-chandigarh/articleshow/95815451.cms">Canada to strengthen visa processing capacity in Delhi and Chandigarh</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/dharmaj-crop-guard-ipo-10-things-to-know-before-subscribing-this-ipo/slidelist/95765888.cms">Dharmaj Crop Guard IPO – 10 things to know before subscribing</a>

Can diabetic drugs help you lose weight? Here’s what experts say

Only 90-some-odd days until next bank-earnings season!The trifecta of JPMorgan, <a href="https://www.businessinsider.com/wells-fargo-records-166-million-tech-expense-in-fourth-quarter-2020-1">Wells Fargo</a>, and Citi, followed by the rest of the Wall Street crowd in the days after, meant a week of early mornings for financial journalists. That's OK, though, since we also get to have some fun parsing testy exchanges on analyst calls - this is, after all, a world where "thanks for that" often means quite the opposite, and "let me try that question again" is basically the webinar version of an all-out brawl. All of that verbal wrangling is part of a quest for "color" - in non-earnings-world speak, that's anything to help decipher the rush of numbers and vague explanations banks throw at you. Luckily, our reporters are always talking to insiders to do just that. <a href="http://newsletter.businessinsider.com/join/4np/wall-st-insider&amp;hash=f4e91136c13f3c40c496d77bc7347502">If you aren't yet a subscriber to Wall Street Insider, you can sign up here</a>Alex Morrell explained <a href="https://www.businessinsider.com/unusual-product-behind-banks-massive-credit-trading-gains-in-2019-2020-1">what's behind a much-welcomed surge</a> in bond-trading revenue across Wall Street. It sure seems like a great time to be an agency mortgage trader - insiders say JPMorgan led the pack there - but it may be a short-lived party. Morgan Stanley is normally among the last to report when it comes to big-bank earnings, but earlier in the week Alex was quick to nab all the names (<a href="https://www.businessinsider.com/morgan-stanley-md-promotions-full-list-of-names-managing-directors-2020-1">here's the list)</a> of its 2020 MD promotes. It's a smaller class than recent years - understandable given the <a href="https://www.reuters.com/article/us-morgan-stanley-layoffs/morgan-stanley-cutting-jobs-due-to-uncertain-global-environment-source-idUSKBN1YD24O">1,500 layoffs</a> the bank announced in December. Oh, and Alex also got the <a href="https://www.businessinsider.com/bank-of-america-sales-and-trading-md-promotions-for-2019-2020-1">names of the new crop</a> of Bank of America sales and trading MDs, and <a href="https://www.businessinsider.com/bank-of-america-is-revamping-bond-trading-division-kotsen-to-depart-2020-1">broke news on a big FICC overhaul</a> there. Dakin Campbell has been covering Goldman Sachs' <a href="https://www.businessinsider.com/latest-goldman-sachs-news-2019-5">huge transformation under CEO David Solomon</a>. Goldman execs told analysts to hang on until the bank's first-ever investor day for the real juicy stuff on its five-year plan. But as Dakin noted, <a href="https://www.businessinsider.com/david-solomon-explains-goldman-private-equity-strategy-shift-2020-1">Solomon did unveil key details</a> this week about transitioning the bank's private investing platform to be more reliant on outside money. To segue out of publicly-traded firms and into the startup space, Bradley Saacks noted that BlackRock CEO Larry Fink <a href="https://www.businessinsider.com/blackrocks-larry-fink-proud-aladdin-made-it-as-a-tech-start-up-2020-1">is "proud"</a> that analytics platform Aladdin is close to topping $1 billion in revenue, a threshold only 3% of tech startups beat. Turns out, the one big secret to startup success that nobody's telling you is being attached to the world's largest asset manager. (BlackRock also blew past a mind-boggling $7 trillion in assets.) That brings us to a call that caught everyone off-guard - this one was for the card folks after Visa announced it would buy buzzy fintech Plaid for $5.3 billion. And as Dan DeFrancesco pointed out, <a href="https://www.businessinsider.com/visa-ceo-mentions-wall-streets-concerns-over-plaid-2020-1">Visa CEO Al Kelly made what might seem like a passing comment</a> that actually has huge implications for the web of financial players that will interact with a Visa-owned Plaid. Not everyone's racing to snap up fintechs, though. As Rebecca Ungarino reported, <a href="https://www.businessinsider.com/bank-of-america-merrill-lynch-andy-sieg-robo-advice-tech-2020-1">Merrill Lynch has zero plans</a> to buy a robo-adviser. That thinking highlights how standalone <a href="https://www.businessinsider.com/robo-advisors-wealthfront-betterment-attract-assets-2020-1">wealth-tech firms may be in a tricky spot</a> as legacy players invest in their own tech. Meanwhile, new startups in the space have ground nearly to a halt. Long reads below, including a deep dive on how exactly pricing algorithms for iBuyers like <a href="https://www.businessinsider.com/six-experts-tell-us-whats-keeping-ibuyers-out-boston-new-york-2020-1">SoftBank-backed Opendoor</a> work; <a href="https://www.businessinsider.com/jamie-dimon-says-business-is-similar-to-software-based-subscriptions-2020-1">Jamie Dimon's argument</a> for why JPMorgan should really be thought of (and valued like) a subscription service; and <a href="https://www.businessinsider.com/kkr-is-about-to-invest-22-billion-in-fast-growing-tech-companies-2020-1">why KKR is looking in unlikely places</a> to invest in tech companies.Have a great weekend, Meredith <h3>Insiders explain how iBuyers like SoftBank-backed Opendoor mix algorithms and human decision-making to flip houses</h3>iBuyers, companies that purchase homes with almost instant all-cash offers, renovate and quickly resell them, were born in 2014 in the heat and sun of Phoenix, Arizona. SoftBank-backed Opendoor, now valued at $3.8 billion, first started purchasing homes in Phoenix that December.By 2015, competitor Offerpad was also buying and flipping homes in Phoenix. The iBuyer model has continued to grow, with established real-estate listing players like Redfin and Zillow entering the fray. There are now active iBuyer markets in almost every region of the US, and even some international regions.While iBuyers have tested new markets, Phoenix's lack of seasonality, an active local economy and housing market, and largely new housing stock has made it the iBuyer capital. <a href="https://www.businessinsider.com/six-experts-tell-us-whats-keeping-ibuyers-out-boston-new-york-2020-1">READ FULL STORY HERE</a><h3>WeWork convinced a skeptical SEC to let it use a wonky metric that tested accounting rules. Here are 58 pages of letters showing how the coworking company changed the agency's mind.</h3>Business Insider obtained 58 pages of correspondence between the SEC and WeWork about the coworking company's IPO filing and questions or concerns the agency had about the document.One crucial piece of the back-and-forth centered on the company's use of a non-GAAP financial metric.The SEC originally asked WeWork to "remove disclosure of this measure throughout your registration statement."After pushback from WeWork's lawyers, including a former chief of the same SEC division asking the company to scrap the metric, the agency relented and allowed the company to continue using the metric after it made some changes. <a href="https://www.businessinsider.com/wework-sec-letters-about-contribution-margin-2020-1">READ THE FULL STORY AND SEE ALL THE DOCUMENTS HERE</a><h3>Jamie Dimon makes renewed pitch for JPMorgan to be valued like a subscription service - and it shows how Wall Street is trying to echo Big Tech</h3>Jamie Dimon may have just a tiny bit of tech envy. The JPMorgan Chase CEO sounded a familiar note on Tuesday on a call with journalists when he casually compared his bank to competitors in Silicon Valley. Answering a question about whether the bank's stellar performance has driven its stock price as high as it will go, Dimon said one aspect of its revenue - much of it being very stable - is similar to a subscription-based model.<a href="https://www.businessinsider.com/jamie-dimon-says-business-is-similar-to-software-based-subscriptions-2020-1">READ THE FULL STORY HERE</a><h3>A KKR exec explained how private equity is looking in unlikely places to invest in tech companies</h3>Private equity firm KKR just raised $2.2 billion to invest in fast-growing tech companies and it will now hunt for deals in regions far beyond Silicon Valley. Dave Welsh, a KKR exec leading its technology media and telecom growth equity unit, said that it would seek investments in areas such as Florida, the greater Washington, D.C., area and Atlanta, as well as the Rocky Mountain region in Colorado and other regions throughout the Midwest.The willingness to go far and wide points to how competition for the best investments across the private equity spectrum is getting stiffer, and more PE firms are getting creative with how they deploy their capital - seeking smaller, including minority, investments.<a href="https://www.businessinsider.com/kkr-is-about-to-invest-22-billion-in-fast-growing-tech-companies-2020-1">READ THE FULL STORY HERE</a><h3>Charles Schwab just pulled the plug on a nearly $100 billion program where rival firms paid to sell ETFs</h3>The broker wars have uncovered some complicated alliances, and it's not always clear who's friend or foe. <a href="https://www.businessinsider.com/category/charles-schwab">Discount broker Charles Schwab</a> just shuttered a nearly $100 billion program where it sold products from third-party asset management giants like State Street, JPMorgan Asset Management, and <a href="https://www.businessinsider.com/category/blackrock">BlackRock</a>.The <a href="https://www.businessinsider.com/category/wealth-management">wealth management</a> and brokerage firm said in its fourth-quarter <a href="https://markets.businessinsider.com/news/stocks/charles-schwab-stock-price-trillions-increased-assets-slashed-fees-q4-2020-1-1028823801">earnings results</a> on Thursday that it discontinued the program, called Schwab ETF OneSource, "as a result of the elimination of online trading commissions for US and Canadian-listed ETFs."The move, completed in the fourth quarter, highlights the tough reality the money-management industry has found itself in following the major brokerages' decisions to <a href="https://www.businessinsider.com/charles-schwab-td-ameritrade-interactive-brokers-e-trade-cut-fees-2019-10">remove online trading fees</a> for stocks and ETFs late last year.<a href="https://www.businessinsider.com/charles-schwab-shuttered-etf-onesource-following-zero-commission-move-2020-1">READ THE FULL STORY HERE</a><h3>Credit Karma has been pegged as a 2020 IPO likely, but its CEO is more focused on developing new products as the $4 billion fintech does more than just free credit scores</h3>Credit Karma, long known for its free credit scores, launched as something of a marketing firm, connecting its users with credit cards and loans and getting paid by the banks that offered those products.But today, it's one of Silicon Valley's hottest fintechs, with a $4 billion valuation and 100 million users. And its audience has grown fast. The 13-year-old company added 75 million users in the last five years alone and says 1 in 2 millennials are on the platform.Reports from the <a href="https://www.wsj.com/articles/tech-ipos-will-face-a-much-higher-bar-11578310200">Wall Street Journal</a> and <a href="https://www.cnbc.com/2019/12/18/tiger-global-and-sequoia-poised-to-cash-in-on-2020-ipos-cb-insights.html">CNBC</a> have pegged Credit Karma as a <a href="https://www.businessinsider.com/ipo-pipeline-2020-report-airbnb-unity-snowflake-sequoia-tiger-global-2019-12">2020 IPO candidate</a>, though its CEO has said <a href="https://www.spglobal.com/marketintelligence/en/news-insights/latest-news-headlines/credit-karma-acorns-among-fintechs-not-seeking-to-go-public-execs-say">he sees listing as a means, not an end</a>, and is more focused on launching new products than going public soon. Credit Karma has <a href="https://techcrunch.com/2017/06/27/credit-karma-number-dump/">indicated it is profitable</a> according to <a href="https://www.bizjournals.com/sanfrancisco/news/2019/04/18/best-places-to-work-2019-credit-karma.html">past media reports. </a>As Credit Karma looks to do more than free credit scores, it's also eyeing the next cohort of spenders - Gen Z.<a href="https://www.businessinsider.com/credit-karma-using-influencers-to-push-products-for-growth-2020-1">READ THE FULL STORY HERE</a> <h3>NOW WATCH: <a href="https://www.businessinsider.com/jennifer-lopez-hustlers-pole-dance-training-2019-9">How Golden Globe nominee Jennifer Lopez trained to pole dance in 'Hustlers'</a></h3>

You Searched For "Dharmaj Crop Guard IPO subscription" and got 4 results

Dharmaj Crop Guard IPO : Here’s how you can check the allotment status

Eetika Kapoor

HealthifyMe sacks about 150 employees, says growth didn't keep pace with hiring

IANS

Can diabetic drugs help you lose weight? Here’s what experts say

Vaamanaa Sethi

Newly minted MDs at Morgan Stanley and Bank of America; unpacking Visa's $5.3 billion Plaid buy

Meredith Mazzilli

Popular Keywords

Buying Guides